Review of the clinical approach to the treatment of disruptive mood dysregulation disorder.
Hendrickson B, Girma M, Miller L.
Int Rev Psychiatry. 2020 May;32(3):202-211. doi: 10.1080/09540261.2019.1688260. Epub 2019 Nov 28.
PMID:31775528
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force.
Ann Clin Psychiatry. 2012 Feb;24(1):23-37.
PMID:22303520
The experience of mood disorder and substance use: An integrative review.
Crowe M, Inder M, Thwaites B.
J Psychiatr Ment Health Nurs. 2023 Jun;30(3):295-308. doi: 10.1111/jpm.12876. Epub 2022 Oct 8.
Malaspina D, Owen MJ, Heckers S, Tandon R, Bustillo J, Schultz S, Barch DM, Gaebel W, Gur RE, Tsuang M, Van Os J, Carpenter W.
Schizophr Res. 2013 Oct;150(1):21-5. doi: 10.1016/j.schres.2013.04.026. Epub 2013 May 23.
PMID:23707642
Interictal Dysphoric Disorder: A disorder with distinct nosography or atypical symptomatology of mood disorders in people with epilepsy? Results from a systematic review.
Conforti H, Massanobu Maekawa R, Roberto Fernandes Lisboa J, Maria de Araújo Filho G.
Epilepsy Behav. 2023 Aug;145:109231. doi: 10.1016/j.yebeh.2023.109231. Epub 2023 Jun 8.
PMID:37300908
Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder.